

[Ethambutol + isoniazid](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AM03](#)

Indication

Tuberculosis ICD11 code: [1B4Z](#)

INN

Ethambutol + isoniazid

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid: 400 mg + 150 mg tablet

EML status history

First added in 1997 ([TRS 882](#))

Removed in 2019 ([TRS 1021](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Ethambutol + isoniazid](#)

[DrugBank](#)

[Ethambutol](#),

[Isoniazid](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the deletion of ethambutol + isoniazid (HE) fixed-dose combination formulation from the core list of the EML, noting the advice of the WHO Global TB Programme that its use is no longer recommended in current WHO guidelines based on evidence that treatment regimens involving this formulation have been associated with greater rates of relapses and death than alternative treatments. The 2010 WHO Treatment of tuberculosis guidelines for the treatment of tuberculosis (1) recommended that the two-month rifampicin regimen, 2HRZE/6HE, should be phased out, based on evidence that showed it to be associated with more relapses and deaths than the six-month rifampicin regimen, 2HRZE/4HR.